Key result
Plasma CTRP9 levels were independently associated with a lower prevalence of moderate/severe obstructive sleep apnea in patients with coronary artery disease (OR 0.726; 95% CI 0.592-0.890; P=0.002).
Why the study?
OSA is linked to CAD incidence and progression, and CTRP9 protects against ischemic injury, but the clinical relevance of CTRP9 to OSA prevalence in CAD was unknown.
Are plasma CTRP9 levels associated with the prevalence of moderate/severe obstructive sleep apnea in patients with coronary artery disease?
Observational (n=154)
Are plasma CTRP9 levels associated with the prevalence of moderate/severe obstructive sleep apnea in patients with coronary artery disease?
Plasma CTRP9 levels are inversely associated with the prevalence of moderate/severe obstructive sleep apnea in patients with coronary artery disease, particularly those with acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
May link CTRP9 to OSA in CAD patients; hypothesis-generating and requires prospective validation before clinical use.
Background. Obstructive sleep apnea (OSA) is closely related to the incidence and progression of coronary artery disease (CAD), and the mechanisms linking OSA and CAD are multifactorial. C1q/TNF-related protein-9 (CTRP9) is a novel adipokine that protects the heart against ischemic injury and ameliorates cardiac remodeling. We aimed to ascertain the clinical relevance of CTRP9 with OSA prevalence in patients with CAD. Methods. From August 2016 to March 2019, consecutive eligible patients with CAD ( n=154 ; angina pectoris, n=88 ; acute myocardial infarction [AMI], n=66 ) underwent cardiorespiratory polygraphy. OSA was defined as an apnea-hypopnea index (AHI) ≥15 events·h−1. Plasma CTRP9 concentrations were measured by ELISA method. Results. Moderate/severe OSA was present in 89 patients (57.8%). CTRP9 levels were significantly decreased in the moderate/severe OSA group than in the no/mild OSA group (4.7 [4.1-5.2] ng/mL vs. 4.9 [4.4-6.0] ng/mL, P=0.003 ). The difference between groups was only observed in patients with AMI (3.0 [2.3-4.9] vs. 4.5 [3.2-7.9], P=0.009 ). Correlation analysis showed that CTRP9 levels were negatively correlated with AHI ( r=−0.238 , P=0.003 ) and oxygen desaturation index ( r=−0.234 , P=0.004 ) and positively correlated with left ventricular ejection fraction ( r=0.251 , P=0.004 ) in all subjects. Multivariate analysis showed that male gender (OR 3.099, 95% CI 1.029-9.330, P=0.044 ), BMI (OR 1.148, 95% CI 1.040-1.268, P=0.006 ), and CTRP9 levels (OR 0.726, 95% CI 0.592-0.890, P=0.002 ) were independently associated with the prevalence of moderate/severe OSA. Conclusions. Plasma CTRP9 levels were independently related to the prevalence of moderate/severe OSA in patients with CAD, suggesting that CTRP9 might play a role in the pathogenesis of CAD exacerbated by OSA.
No takes yet. Share an insight, caveat, or question.
Li et al. (2020) conducted an observational in Coronary artery disease and obstructive sleep apnea (n=154). Plasma CTRP9 levels was evaluated on Prevalence of moderate/severe obstructive sleep apnea (OR 0.726, 95% CI 0.592-0.890, p=0.002). Plasma CTRP9 levels were independently associated with a lower prevalence of moderate/severe obstructive sleep apnea in patients with coronary artery disease (OR 0.726; 95% CI 0.592-0.890; P=0.002).
Synapse has enriched 10 related papers. Consider them for comparative context: